#ACMT2024 | NIDA Research & ED Experience with XR Injectable Buprenorphine

Kristen Huntley, PhD, is the Associate Director and Addiction Medicine Team Leader in the Center for the Clinical Trials Network (CCTN), National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH). Dr. Huntley also serves as a Scientific Officer for multi-site clinical research projects studying the effectiveness and implementation of interventions for the treatment of substance use disorders. She provides leadership for selected projects conducted through the NIDA CTN Dissemination Initiative, and is the NIDA CCTN contact for research conducted in emergency medicine settings. 

During her tenure at NIH Dr. Huntley has served as a Scientific Review Officer at NIDA and as a Program Director at the National Center for Complementary and Integrative Health (NCCIH) where she managed a portfolio of pain management research grants and led efforts to build collaborations with other federal agencies to encourage research on the use of integrative approaches and models of care for pain management in military and veteran populations. Prior to working at NIH, Dr. Huntley was on the faculty of Case Western Reserve University School of Medicine, a project director at a market research firm, and worked as a clinical psychologist in a variety of community and medical settings. Dr. Huntley has a Ph.D. in clinical psychology and over 30 years of experience in government, academic, research, and clinical settings.

Dr. D’Onofrio is the Albert E. Kent Professor of Emergency Medicine, and Professor of Medicine and Public Health at Yale School of Medicine.  She is boarded in emergency medicine and Addiction Medicine. An independent NIH-funded physician-scientist with over two decades of experience designing and implementing clinical trials in the ED setting related to alcohol and drug use, her work (JAMA, 2015) demonstrating that ED-initiated buprenorphine increases engagement in addiction treatment for individuals with OUD, has changed clinical practice. 

Dr. D’Onofrio has a long track record of mentoring physician scientists in independent research careers. She is the PI of a NIDA K12 establishing the Yale Drug Use, Addiction and HIV Research Scholars (Yale-DAHRS) program, a Mentored Career Development Program with focused training in prevention and treatment of drug use, addiction, and HIV in general medical settings with scholars in multiple medical specialties. Dr. D’Onofrio is the PI of the New England Consortium Node, for the NIDA Clinical Trials Network. Dr. D’Onofrio is a founding Board member of the Board of Addiction Medicine now recognized by ABMS as a Specialty, Sub-specialty under Preventive Medicine.  She partners with multiple agencies regionally and nationally to change policies and introduce interventions to combat the opioid crisis and was recently inducted into the National Academy of Medicine.   

Joseph Carpenter, MD is an Assistant Professor in the Medical Toxicology Section, Department of Emergency Medicine at the Emory University School of Medicine. He is a graduate of Brown University and the Stanford University School of Medicine. Dr. Carpenter completed his residency in emergency medicine at Los Angeles County Harbor-UCLA Medical Center and fellowship in medical toxicology at Emory University and the Centers of Disease Control and Prevention.  

His clinical time is split between Grady Memorial Hospital’s emergency department, medically assisted opioid treatment clinic, and medical toxicology consultation service, as well as the Georgia Poison Center. He is the director of research for Emory’s Medical Toxicology Section, and his research interests lie at the growing intersection of emergency medicine, medical toxicology, and addiction medicine. He has received over $5 million in federal research funding as PI or site PI dedicated to improving hospital-based treatment for patients with substance use disorders.

Jon Cole is a medical toxicologist and emergency physician at Hennepin Healthcare in Minneapolis, Minnesota. He is Professor of Emergency Medicine at the University of Minnesota Medical School and has been Medical Director of the Minnesota Poison Control System since 2011. He has published extensively in emergency medicine and toxicology, focusing on emergency pharmacology, management of drug-induced shock and delirium, and care of patients with substance use disorders in the emergency department.

Timothy J. Wiegand, MD, FACMT, FAACT, DFASAM is an Associate Professor of Emergency Medicine and Public Health Sciences at the University of Rochester Medical Center in Rochester New York.  He is Board Certified in Medical Toxicology and Addiction Medicine and practices in Addiction Toxicology with a mix of clinical,  research, teaching, and other professional work.  Dr. Wiegand has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and he is currently serving on the Board of Directors for the American Society of Addiction Medicine (ASAM) completing a term on the Executive Counsel as Vice President of ASAM.  He begins a two-year term as Treasurer of ASAM in April 2023.  Dr. Wiegand founded and led the Toxicology service at URMC until 2022 when he became Director of Addiction Medicine and Director of Addiction Medicine Consults also at URMC in the Department of Emergency Medicine.  Dr. Wiegand has served as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and he is the Fellowship Director for the URMC Medical Toxicology fellowship expecting to formally begin once accredited, in July of 2023.